Please login to the form below

Not currently logged in

Former Roche development head joins Asana advisory board

Dr Kapil Dhingra also brings experience from Lilly

Asana BioSciences Dr Kapil DhingraAsana BioSciences has appointed former head of Roche oncology clinical development Dr Kapil Dhingra to its oncology scientific advisory board.

Dr Dhingra served at Roche from 1999 to 2008, most recently as vice president, head of the Swiss pharma company's oncology disease biology leadership team and head of oncology clinical development.

Prior to that he worked at Lilly as a clinical research physician having previously served at the faculty of M.D. Anderson Cancer Center in Houston, Texas, where he pursued laboratory and clinical cancer research.

Dr Sandeep Gupta, founder, president and CEO of New Jersey-based Asana Biosciences, said: “We welcome Dr. Dhingra to our oncology scientific advisory board. His expertise, proven track record and strategic insights will be great assets to Asana.

I look forward to working closely with him and other SAB members in advancing our robust and differentiated oncology pipeline further into clinical development.”

The founder of KAPital Consulting, Dr Dhingra currently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications, Five Prime and Autolus.

11th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...